Treatment of Bullous Pemphigoid in Elderly Patients

First-Line Treatment

The American College of Dermatology recommends superpotent topical corticosteroids, such as clobetasol propionate 0.05% cream, as the first-line treatment for elderly patients with bullous pemphigoid, providing superior disease control with significantly lower mortality compared to systemic corticosteroids 1, 2
For localized disease, apply clobetasol propionate directly to lesions only, for mild widespread disease apply to the whole body except face using 20g/day, and for generalized disease apply to the entire body except face using 20g/day 1
Begin tapering after 15 days once disease control is achieved and reduce to maintenance therapy of 10g once weekly after 4 months 1

For patients who cannot apply topical steroids or those at high risk for steroid complications, the European Dermatology Society recommends doxycycline 200mg/day combined with nicotinamide, achieving a 73.8% response rate with reduced mortality 1, 2

Dupilumab is the first-line biologic choice for elderly patients with bullous pemphigoid, particularly when conventional therapies fail or are contraindicated, with a dosing regimen of 600mg subcutaneously initially, followed by 300mg every 2 weeks 2
Dupilumab reduces systemic glucocorticoid use by 82.1% by week 52 and has a safety profile with only 12.6% of patients experiencing adverse events, most mild, with no dupilumab-related serious adverse events recorded 2

If systemic corticosteroids are necessary, the National Institute for Health and Care Excellence recommends combining azathioprine with low-dose prednisone to reduce steroid dose by approximately 45% 1, 2

The British Association of Dermatologists advises against using high-dose systemic corticosteroids (>40mg prednisolone daily) as first-line therapy in elderly patients, as this approach doubles mortality risk 3
Approximately 50% of drug-induced bullous pemphigoid cases persist and require conventional treatment, even after drug withdrawal 1
Bullous pemphigoid has a significant association with neurological disorders, including dementia, Parkinson's disease, and stroke, which may complicate treatment adherence 1